Document:

Prepared by R.R. Donnelley Financial -- Special Severance Pay Plan

 Exhibit 10.40 
  
 2002 SPECIAL SEVERANCE PAY PLAN 
 FOR AMGEN EMPLOYEES 
  
 This Plan provides severance benefits to employees of Amgen Inc. (“Amgen”) and its subsidiaries (collectively, the “Employer”) who meet the requirements
set forth in Section 1 of this Plan. The Plan is administered by Amgen, which is the Plan Administrator. 
  
 1.  Eligibility 
  
 (a)  Generally, an employee will be eligible for this
Plan if he or she is subject to one of the following qualifying events: 
  
 (i)  Group
termination or job elimination.    Termination due to group terminations or job eliminations designated by Amgen as qualifying events. 
  
 (ii)  Job restructuring or reclassification.    Down grades of two salary grades or more as a result of job
restructuring or reclassification, or reclassifications of a part-time position to a full-time position, designated by Amgen as qualifying events. This is not intended to include staff members who are demoted for performance or disciplinary reasons.

  
 (iii)  Relocation.    Terminations due to employee’s
refusal of Employer’s request to relocate employee’s principal place of employment to a location more than 50 miles or more from that employee’s current principal place of employment. 
  
 However, the Plan Administrator may, in its sole discretion, determine from time to time that an employee is eligible for this Plan even if he or she does not
experience one of the foregoing qualifying events. 
  
 (b)  Notwithstanding the foregoing, employees who
are eligible for severance benefits under the following arrangements shall not also be eligible for this Plan unless the Plan Administrator determines otherwise in its sole discretion: 
  
 (i)  the Immunex Corporation Amended and Restated Leadership Continuity Policy; 
  
 (ii)  the Immunex Corporation Employee Severance Plan; 
  
 (iii)  the Immunex Corporation Severance Plan; 
  
 (iv)  the Purchase Agreement among American Home Products Corporation, AHP Subsidiary Holding Corporation, and Immunex Corporation; or

  
 (v)  any individual severance agreement. 
  
 (c)  Each employee who is eligible for this Plan shall be hereafter referred to as a “Participant” 

 
 2.  Benefits 
  
 (a)  Basic Benefit 
  
 Each Participant will receive a
Basic Benefit of one month of Base Pay, as set forth on the benefit schedule attached to this Plan. “Base Pay” shall mean the Participant’s base salary or wages (excluding overtime pay, bonuses, commissions, premium pay, shift

 

 1 

 differentials, MIP VEP, SRA, Stock Options, and/or other compensation) immediately prior to the last date of employment. The base monthly rate
of pay of a Participant who is paid by the hour shall be his or her regular hourly rate multiplied times his or her regularly scheduled hours per week (which is 40 for full-time employees). The Plan Administrator’s determination of Base Pay
shall be final and binding. 
  
 (b)  Enhanced Benefit 
  

If a Participant agrees to terminate employment on good terms with the Employer by signing the release form prescribed by the Plan Administrator (“Release”)
and filing the Release with the Plan Administrator within the time period prescribed by the Plan Administrator, the Participant shall receive an Enhanced Benefit in addition to his or her Basic Benefit payable under Section 2(a). This Enhanced
Benefit are set forth on the benefit schedule attached to this Plan. 
  
 (c)  Form of Payment 

 
 (i)  Basic and Enhanced Benefits payable under Sections 2(a) and (b) normally shall be paid as a cash
lump sum subject to withholding as set forth under Section 3(a). 
  
 (ii)  A
Participant’s Basic and Enhanced Benefits shall commence immediately after the Participant’s last day of work, or as soon thereafter as is administratively practical. 
  
 (iii)  A Participant shall not be an employee of the Employer during his or her Salary Continuation period. 
  
 (d)  Additional Benefits 
  
 A Participant who receives Enhanced Benefits shall also be eligible for the following Additional Benefits: 
  
 (i)  The Participant shall be offered outplacement counseling services selected by the Plan Administrator for the number of weeks of outplacement
benefits shown on the benefit schedule attached to this Plan. 
  
 (ii)  A Participant who
purchases medical, dental or vision COBRA continuation coverage for himself or herself or for his or her spouse or dependents in accordance with the Employer’s customary COBRA procedures and rules shall not be required to pay for that coverage
period of time specified on the benefit schedule attached to this Plan. Thereafter, normal COBRA premiums shall be charged. “COBRA” refers to the health care continuation requirements of Part 6 of Title I of the Employee Retirement Income
Security Act of 1974. 
  
 (e)  Integration with WARN Act and Similar Laws 
  
 A Federal law, the WARN Act, requires that advance notice be given to employees of certain layoffs. Other laws may impose similar notice
requirements or require that pay-in-lieu-of-notice, waiting-time penalties, severance pay, or similar benefits be paid. The Employer shall be entitled to subtract from any benefits payable to a Participant under this Plan any other amount it is
legally required to pay to the Participant under such laws, plus any compensation and benefits paid to the Participant following distribution of such a legally-required notice of termination to the Participant. Similarly, benefits paid under this
Plan shall be applied to satisfy any legal obligations the Employer may have under such laws. This subsection 
 

 2 

 shall also apply with respect to any amounts payable to a Participant under any employment law or doctrine on account of his or her termination
of employment. The reductions authorized by this subsection shall be effected in the manner specified by the Plan Administrator, however, they shall not have the effect of reducing a Participant’s Enhanced Benefit below the equivalent of one
month Base Pay. 
  
 (f)  Notwithstanding the foregoing, the Plan Administrator may, in its sole discretion,
determine from time to time that different benefits be payable, or that such benefits not be subject to section 2(e). 
  
 3.  Other Rules 
  
 (a)  Taxes 
  
 Income and payroll taxes shall be withheld from benefits under the Plan as the Employer determines to be required by law. 

 
 (b)  Relation to Other Plans 
  
 Benefits under this Plan shall not be counted as “compensation” for purposes of determining benefits under any other benefit plan or similar arrangement of the Employer or its affiliates, and
all such plans or similar arrangements, to the extent inconsistent, are hereby so amended. 
  
 (c)  Effective Date, Plan Year, Amendment, and Termination of Plan 
  
 This Plan is
intended to be a temporary plan. It went into effect on January 1, 2002, and it shall expire when the Plan Administrator determines that no more Basic or Enhanced Benefits will be payable (although outplacement and subsidized COBRA benefits shall
remain payable for the full period prescribed in Section 2(b)). The Plan’s Plan Year is the 12-month period ending on December 31. Amgen Inc., acting through its Vice President of Human Resources, shall have the right, in its non-fiduciary
capacity as settlor, to amend the Plan or to terminate it at any time (by a formal, written, and explicit instrument), prospectively or retroactively, for any reason, without notice to Employees or Participants and even if currently payable benefits
are reduced or eliminated. No person shall have any vested right to benefits under this Plan. By letter or other written notice to an Employee, the Plan Administrator may elect to increase or decrease Plan benefits, or otherwise modify the terms of
the Plan, as to that Employee. 
  
 (d)  Claims Procedure 
  
 (i)  Normally, a Participant need not present a formal claim in order to qualify for rights or benefits under
this Plan. However, if any person (“Claimant”) does not believe he or she will receive the benefits to which the person is entitled or believes that the Plan is not being operated properly, that fiduciaries of the Plan have breached their
duty, or that his or her own legal rights are being violated with respect to the Plan, the Claimant must file a formal claim under the procedures set forth in this section. A formal claim must be filed within 90 days of the date on which the
Claimant (or his or her predecessor in interest) first knew (or should have known) of the facts which the claim is based, unless the Plan Administrator in writing consents otherwise. The procedures in this section shall apply to all claims that any
person has with respect to the Plan, including claims against fiduciaries and former fiduciaries, except to the 
 

 3 

 extent the Plan Administrator determines, in its sole discretion, that it does not have the power to grant, in substance,
all relief reasonably being sought by the Claimant. 
  
 (ii)  A claim by any person shall
be presented to the Plan Administrator in writing. A claims official appointed by the Plan Administrator shall, within 90 days of receiving the claim, consider the claim and issue his or her determination thereon in writing. The claims official may
extend the determination period for up to an additional 90 days by giving the Claimant written notice. If the claim is granted, the benefits or relief the Claimant seeks will be provided. 
  
 (iii)  If the claim is wholly or partially denied, the claims official shall, within 90 days (or such longer period as described above), provide
the Claimant with written notice of the denial, setting forth, in a manner calculated to be understood by the Claimant: 
  
 a.  the specific reason or reasons for the denial; 
  
 b.  specific references to pertinent Plan provisions on which the denial is based; 
  
 c.  a description of any additional material or information necessary for the Claimant to perfect the claim and an explanation of why the material or information is necessary; and 
  
 d.  an explanation of the Plan’s claim review procedure. 
  
 With the consent of the Claimant, this determination period can be extended further. If the claims official fails to respond to the claim
in a timely manner, the Claimant may treat the claim as having been denied by the claims official. 
  
 (iv)  Each Claimant shall have the opportunity to appeal in writing the claims official’s denial of a claim to a review official designated by the Plan Administrator (which may be a person or a committee) for a full
and fair review. A Claimant must request review of a denied claim within 60 days after receipt by the Claimant of written notice of denial of his or her claim or within 60 days after such written notice was due, if the written notice was not sent.
In connection with the review proceeding, the Claimant or his or her duly authorized representative may review pertinent documents and may submit issues and comments in writing. The Claimant may only present evidence and theories during the review
that the Claimant presented during the claims procedure, except for information that the claims official requested the Claimant to provide to perfect the claim (see clause (iii)(c)). Any claims that the Claimant does not in good faith pursue through
the review stage of the procedure shall be treated as having been irrevocably waived. 
  
 (v)  The Plan Administrator shall adopt procedures pursuant to which claims shall be reviewed and may adopt different procedures for different claims without being bound by past actions. Any procedures adopted, however,
shall be designed to afford a Claimant a full and fair review of his or her claim. 
  
 (vi)  The decision by the review official review of a claim shall be made not later than 60 days after the written request for review is received by the Plan Administrator, unless special circumstances require an extension
of time for processing, in which case a 
 

 4 

 decision shall be rendered as soon as possible, but not later than 120 days after receipt of the request for review,
unless the Claimant agrees to a greater extension of that deadline. 
  
 (vii)  The review
decision shall be in writing and shall include specific reasons for the decision written in a manner calculated to be understood by the Claimant, with specific references to the pertinent Plan provisions on which the decision is based. 

 
 (viii)  The Plan Administrator shall modify these claim procedures without amending the Plan to the
extent it determines modifications are appropriate to comply with applicable law. 
  
 (e)  Effect of
Fiduciary Action 
  
 (i)  The Plan shall be interpreted by the Plan Administrator and all
Plan fiduciaries in accordance with the terms of the Plan and their intended meanings. However, the Plan Administrator and all Plan fiduciaries shall have the discretion to make any findings of fact needed in the administration of the Plan, and
shall have the discretion to interpret or construe ambiguous, unclear or implied (but omitted) terms in any fashion they deem to be appropriate in their sole judgment. The validity of any such finding of fact, interpretation, construction, or
decision shall not be given de novo review if challenged in court, by arbitration, or in any other forum, and shall be upheld unless clearly arbitrary or capricious. 
  
 (ii)  To the extent the Plan Administrator or any Plan fiduciary has been granted discretionary authority under the Plan, the Plan
Administrator’s or Plan fiduciary’s prior exercise of such authority shall not obligate it to exercise its authority in a like fashion thereafter. 
  
 (iii)  If, due to errors in drafting, any Plan provision does not accurately reflect its intended meaning, as demonstrated by consistent
interpretations or other evidence of intent, or as determined by the Plan Administrator in its sole and exclusive judgment, the provision shall be considered ambiguous and shall be interpreted by the Plan Administrator and all Plan fiduciaries in a
fashion consistent with its intent, as determined by the Plan Administrator. The Plan Administrator shall amend the Plan retroactively to cure any such ambiguity, notwithstanding anything in the Plan to the contrary. 
  
 (iv)  This Section may not be invoked by any person to require the Plan to be interpreted in a manner that is
inconsistent with its interpretation by the Plan Administrator or by any Plan fiduciaries. All actions taken and all determinations made in good faith by the Plan Administrator or by Plan fiduciaries shall be final and binding on all persons
claiming any interest in or under the Plan. 
  
 (f)  Duties of the Plan Administrator 

 
 The Plan Administrator shall be responsible for the general administration and management of the Plan. The Plan Administrator
shall have all powers and duties necessary to fulfill its responsibilities, including, but not limited to, the following powers and duties: 
  
 (i)  To interpret and apply the Plan as it, in its sole discretion, determines to be appropriate; and 
  
 (ii)  To determine all questions relating to the eligibility of persons to participate or receive benefits as it, in its sole discretion, deems to
be appropriate. 
 

 5 

  
 (g)  Costs and Indemnification 
  
 All costs of administering the Plan shall be paid by the Employer, with one exception: Any expenses incurred in resolving disputes among
different Claimants as to their entitlement to a Plan benefit shall be charged against the benefit, which shall be reduced accordingly. To the extent permitted by applicable law, the Employer shall indemnify and save harmless its officers,
directors, and employees against any and all expenses, liabilities, and claims (including legal fees incurred to defend against such liabilities and claims) arising out of their discharge in good faith of their administrative and fiduciary
responsibilities with respect to the Plan. Expenses and liabilities arising out of willful misconduct shall not be covered under this indemnity. This indemnity shall not preclude such further indemnities as may be available under insurance purchased
by the Employer or provided by the Employer or under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. 
  
 (h)  Duty To Provide Data 
  
 Every person claiming a benefit under this Plan is
responsible for informing the Plan Administrator of his or her mailing address and each change of mailing address. If a person fails to give notice of his or her correct address, the Plan Administrator, the Employer, and Plan fiduciaries shall not
be obliged to search for, or to ascertain, his or her whereabouts. 
  
 (i)  Limitation on Rights of
Employees 
  
 The Plan is strictly a voluntary undertaking on the part of the Employer and shall not constitute a
contract between the Employer and any person, or consideration for, or an inducement or condition of, the employment of any employee. Except as otherwise required by statute, nothing in the Plan shall give any employee the right to be retained in
the service of the Employer or to interfere with or restrict the right of the Employer, which is hereby expressly reserved, to discharge or retire any employee at any time for any reason not prohibited by statute, without the Employer being required
to show cause for the termination. Except as otherwise required by statute, inclusion under the Plan will not give any employee any right or claim to any benefit hereunder except to the extent such right has specifically become fixed under the terms
of the Plan. The doctrine of substantial performance shall have no application to employees or Participants. Each condition and provision, including numerical items, has been carefully considered and constitutes the minimum limit on performance that
will give rise to the applicable right. 
  
 (j)  Governing Law 
  
 The Plan shall be interpreted, administered and enforced in accordance with the Employee Retirement Income Security Act of 1974, and the
rights of Participants and all other persons shall be determined in accordance with that law. To the extent that state law is applicable, however, the statutes and common law of the State of California (excluding its choice of laws doctrines) shall
apply. 
  
 (k)  Status of Plan 
  
 This Plan is a welfare plan subject to ERISA. 
 

 6 

  
 (l)  Plurals 
  
 Where the context so indicates, the singular shall include the plural and vice versa. 
  
 (m)  Titles 
  
 Titles are
provided herein for convenience only and are not to serve as a basis for interpretation or construction of the Plan. 
  
 (o)  References 
  
 Unless the context clearly indicates to the contrary, a reference to a
statute or document shall be construed as referring to any subsequently enacted, adopted, or executed counterpart. 
  
 To record the Plan as set forth herein, effective as of January 1, 2002, the Company has caused its authorized officer to execute the same this 25th day of July, 2002. 
  
 
	 AMGEN INC.
 
	 
	 By:
 	 	 /s/    BRIAN
MCNAMEE        
 

	  	 	 Brian McNamee
 Senior Vice
President, Human Resources
 

 
 

 7 

 Amgen Severance Plan (as of March 5, 2002) 
  
 
	  	 	 Group A
 Grades 11 to 21
 
	 	 Group B
 Grades 22 to 27
 
	 	 Group C
 Grades 28, 29, L1
 
	 	 Group D
 Grades 30, 31, L2, L3
 
	 	 Group E
 Grades 32, 33
 

	 Base Severance
 Amount
 	 	 1 month of Base Pay(1)(2)
 	 	 1 month of Base Pay(1)(2)
 	 	 1 month of Base Pay(1)(2)
 	 	 1 month of Base Pay(1)(2)
 	 	 1 month of Base Pay(1)(2)
 
	 
	 Enhanced Severance Benefits(3)
 	 	  	 	  	 	  	 	  
	 
	 •   Additional Base Severance
 	 	 2 months of Base Pay
 	 	 2 months of Base Pay
 	 	 2 months of Base Pay
 	 	 5 months of Base Pay
 	 	 1 year of Base Pay and
 Incentive(4)
 (less the Base
 Severance Amount)

	 •   Service Premium
 	 	 2 weeks Base Pay for
 each
year of service
 (rounded up)(5)
 	 	 2 weeks Base Pay for
 each year of
service
(rounded up)(5)
 	 	 2 weeks Base Pay for
 each year
of service
 (rounded up)(5)
 	 	 2 weeks Base Pay for
 each year
of service
 (rounded up)(5)
 	 	 —  
 
	 
	 Additional Severance Benefits(3)
 	 	  	 	  	 	  	 	  
	 
	 •   Company-Subsidized     COBRA (6)
 	 	 For length of severance period (7)
 	 	 For length of severance period (7)
 	 	 For length of severance period (7)
 	 	 For length of severance period (7)
 	 	 For length of severance period (7)
 
	 
	 •   Outplacement Services(8)
 	 	 1 month
 	 	 3 months
 	 	 6 months
 	 	 6 months
 	 	 12 months
 
	 
	 Minimum Base
 Severance
 	 	 1 month of Base Pay
 (without signing Severance Agreement)

or
 4 months of Base Pay(9)
 	 	 1 month of Base Pay
 (without signing Severance Agreement)

or
 4 months of Base Pay(9)
 	 	 1 month of Base Pay
 (without signing Severance Agreement)

or
 4 months of Base Pay(9)
 	 	 1 month of Base Pay
 (without signing Severance Agreement)

or
 6 months of Base Pay(9)
 	 	 1 month of Base Pay
 (without signing Severance Agreement)

or
 1 year of Base Pay and Incentive(9)
 
	 
	 Maximum Base Severance
 	 	 12 months of Base
 Pay
 	 	 12 months of Base
 Pay
 	 	 12 months of Base
 Pay
 	 	 12 months of Base
 Pay
 	 	 1 year of Base Pay
 and Incentive
 

 
 

	(1)
	 
	“Base Pay” shall mean the Eligible Employee’s base salary or wages (excluding overtime pay, bonuses, commissions, premium pay, shift
differentials, MIP, VEP, SRA, Stock Options, and/or other compensation) immediately prior to the last date of employment. 
 

	(2)
	 
	The Company shall be entitled to withhold from amounts to be paid to the severed Employee any federal, state or local withholding or other taxes which it is
from time to time required by law to withhold. 
 

	(3)
	 
	Enhanced and Additional Severance Benefits are provided only if Eligible Employee executes and does not revoke Severance Agreement. 

 

 8 

  

	4
	 
	“Incentive” shall mean the Eligible Employee’s target annual bonus (target % multiplied by annual base salary) immediately prior to the last date
of employment. 
 

  

	5
	 
	“Years of Service” shall mean, beginning on the Eligible Employee’s date of hire, each full and partial year of an Eligible Employee’s
employment by the Company. 
 

  

	6
	 
	So long as Eligible Employee and/or eligible dependents timely take the required steps to initiate such coverage. COBRA benefits are provided for the length of
the severance period or until Eligible Employee and/or eligible dependents no longer qualify for COBRA continuation benefits, whichever is earlier. 
 

  

	7
	 
	“Severance Period” shall mean with respect to each Group A, B, and C employee, three (3) months plus the number of weeks equal to two (2) times such
Employee’s Years of Service. With respect to each Group D employee, it shall mean six (6) months plus the number of weeks equal to two (2) times such Employer’s Years of Service. With respect to each Group E employee, it shall mean one (1)
year. 
 

  

	8
	 
	Outplacement Services are provided for the lengths of time indicated above or until employee becomes re-employed, whichever is earlier. 

  

	9
	 
	Only if Eligible Employee executes and does not revoke Severance Agreement. 
 

  
 This form is intended to be used for informational purposes only. Nothing in this form or told to you by any Amgen employee is a contract or an offer of a contract.
Neither this form nor anything told to you by any Amgen employee creates a legally enforceable right or expectancy in any staff member. To the extent that this form or anything told to you by any Amgen employee differs from what is provided you in
your Severance Agreement, the Severance Agreement controls. Additionally, nothing in this document modifies the at-will nature of employment at Amgen. 
 

 9Prepared by R.R. Donnelley Financial -- Amendment No. 2 To Enbrel Supply Agreement

  
 
 
 *Certain
confidential information contained in this document, marked by the brackets, has been omitted and filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
 
 
 EXHIBIT 10.77 
  
 AMENDMENT NO. 2 
 TO THE 

 ENBREL® SUPPLY AGREEMENT 
  
 This Amendment No. 2
(“Amendment No. 2”) is made this 3rd day of June, 2002 (the “Amendment No. 2 Effective Date”) by and among IMMUNEX CORPORATION, a corporation of the State of Washington, having its principal place of business at 51
University Street, Seattle, Washington 98101, U.S.A., together with its Affiliates (“Immunex”), WYETH (formerly known as American Home Products Corporation), a corporation of the State of Delaware having its corporate headquarters
at Five Giralda Farms, Madison, New Jersey 07940, U.S.A. (“Wyeth”), and BOEHRINGER INGELHEIM PHARMA KG, a German corporation having a place of business at Birkendorfer Straße 65, 88397 Biberach an der Riss, Federal Republic of
Germany (“BIP”), and amends the Enbrel Supply Agreement effective as of November 5, 1998, by and among Immunex, Wyeth, and BIP, and amended in Amendment No. 1 as of June 27, 2000 (the “Agreement”).

  
 WHEREAS, Immunex, Wyeth and BIP have entered into a certain Agreement for BIP’s supply of
Enbrel® (etanercept) to Immunex and Wyeth; 
  
 WHEREAS, the Parties have determined that it would be advantageous for the manufacture of Enbrel to be relocated from the Original
Biberach Facility, also known as H84, to [*], known as the [*] (the “[*] Biberach Facility”); 
  
 WHEREAS, the Parties have also determined that it would be advantageous to change the [*] for manufacturing Enbrel from the [*]; 
  
 WHEREAS, the development work related to the transfer to the [*] is addressed in the [*]; and 
  
 WHEREAS, pursuant to Section 23.9 of the Agreement, the Agreement may only be amended and supplemented by a written instrument signed by the Parties. 
  
 NOW THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereto, each intending to be legally bound, hereby agree as follows: 
  
 1.  Capitalized Terms.    All initially capitalized terms used herein and not defined shall have the meanings set forth in the Agreement. 
 

	*
	 
	Confidential Treatment Requested. 
 

  
 2.  Amended Definitions.    Section 1.36 and
1.56 of the Agreement shall be amended and restated to read as follows: 
  
 1.36 [*] 

 
 1.56 [*] 
  
 3.  New Definitions.    Section 1.66 of the Agreement shall be amended to add the following new definitions: 
  

	  	  	 Section
 

	 “Additional H84 Unused Capacity”
 	  	 5.10(a)(4)
 
	 “Baseline Accepted Unused Capacity”
 	  	 5.10(a)(4)
 
	 [*]
 	  	 5.3(c)(i)
 
	 [*]
 	  	 5.3(c)(iii)
 
	 [*]
 	  	 5.3(c)(iii)
 
	 “Post-Transition Years”
 	  	 5.10(a)(3)
 
	 [*]
 	  	 3.5(b)(3)
 
	 “[*]Pricing Runs”
 	  	 24.1(g)
 
	 “Transition Years”
 	  	 5.10(a)(2)
 

 
  
 4.  Relocation [*].    A new
Section 3.5 shall be added to the Agreement as follows: 
  
 3.5  Relocation of Manufacturing and
[*]. 
  
 (a)  Relocation.    BIP shall undertake to relocate
manufacture of the Product from the Original Biberach Facility to the [*] Biberach Facility, by performing the activities set forth on Amendment No. 2 Exhibit A and in accordance with the schedule set forth on Amendment No. 2
Exhibit B, each of which is attached hereto and made a part hereof. 
  
 (b)  Conversion to [*] 
  
 (1)  BIP shall undertake to convert
from manufacturing the Product using the [*] to using the [*] by performing the activities set forth on Amendment No. 2 Exhibit A. Subject to Section 3.5(b)(2) below, BIP shall use all commercially reasonable efforts to convert manufacture of the
Product [*] as soon as reasonably practicable. 
  
 (2)  BIP shall begin manufacturing in
the [*] Biberach Facility using the [*] and shall continue to perform the conversion activities described in Section 3.5(b)(1) above, according to the schedule set forth on Amendment No. 2 Exhibit B attached hereto and made a part hereof.
Immunex and Wyeth shall bear the additional costs of 
 

	*
	 
	Confidential Treatment Requested. 
 

 

 2 

  
 the activities associated with using the [*] in the [*] Biberach Facility, which
activities and costs are described on Amendment No. 2 Exhibit C attached hereto and made a part hereof. In the event that the Parties mutually agree to delay conversion to [*] beyond the schedule set forth in Amendment No. 2 Exhibit B, the
Parties shall agree in writing on revised versions of Amendment No. 2 Exhibit A and Amendment No. 2 Exhibit B, as applicable, by incorporating the changes as are appropriate under the circumstances. 
  
 (3)  Notwithstanding the foregoing, the [*] will not be used to manufacture Product in any other commercial
manufacturing facility in the world prior to its implementation in the [*] Biberach Facility, except that Immunex may at its discretion use [*] to manufacture Product at [*] prior to use of such [*] in the [*] Biberach Facility. In the event that
[*] is used in the [*] prior to its use in the [*] Biberach Facility, then (i) the Parties shall cooperate in good faith to transfer all applicable data and information about the [*] to BIP to facilitate implementation of [*] into the [*] Biberach
Facility, and (ii) Immunex and Wyeth shall use all commercially reasonable efforts to facilitate BIP’s validation and launch of the [*] to manufacture commercial Product in the [*] Biberach Facility within one (1) year following initial use of
such [*] to manufacture commercial Product [*]. 
  
 5.  Maximum Request; Annual Minimum; Unused
Production Capacity.    Section 5.10(a) of the Agreement shall be amended and restated as follows: 
  
 5.10  Maximum Request; Annual Minimum. 
  
 (a)  Maximum
Request. 
  
 (1)  Maximum Request.    Subject to Section
5.10(c) below, beginning on [*] and continuing through [*], the annual Maximum Request in the Agreement shall be equal to the Annual Minimum as defined in Section 5.10(b) below. Immunex and Wyeth hereby waive their ability to reduce the Maximum
Request below the Annual Minimum under Section 5.1(b) hereof until an effective date of [*] at the earliest, except to the extent otherwise permitted in Section 5.10(c) below. Subject to Section 5.10(c) below, beginning on [*] and continuing through
the end of the Supply Term, Immunex and Wyeth shall be entitled to reduce the Maximum Request (unless otherwise agreed in writing among the Parties, to be calculated by using the original Maximum 
 

	*Confidential
	 
	Treatment Requested. 
 

 

 3 

 Request herein) by no more than [*] percent ([*]%) per Calendar Year by providing at least the required [*] prior written
notice to BIP (e.g., notice by [*] for a potential reduction in the Maximum Request effective as of [*], etc.). Moreover, the absolute minimum of the Maximum Request after permitted reductions under Section 5.1(b) of the original Agreement shall
always be the required capacity for [*] of Bulk Drug Substance calculated in accordance with the original Production Assumptions herein. 
  
 In addition to the Maximum Request, BIP shall be bound to provide the following Bulk Drug Substance Runs in the Original Biberach Facility to Immunex and Wyeth: 
  
 (i)  To the extent that BIP acquires any Original Additional Run or Subsequent Additional Run as a result of
its Outsourcing Activities, (A) all such Original Additional Runs shall be reserved for Buyer through [*] and (B) Buyer shall have a ROFR for any Subsequent Additional Run during Calendar Years [*] and [*], and such ROFR shall be exercised according
to Section 24.1(d)(2) hereof. 
  
 (ii)  To the extent that BIP enters into a binding
commitment, pursuant to Section 5.10(a)(2) below, to provide a number of Bulk Drug Substance Runs that exceeds the Maximum Request in a Transition Year, such commitment shall be binding on the Parties. 
  
 (iii)  BIP shall provide the Baseline Accepted Unused Capacity, as well as any Additional H84 Unused Capacity
reserved by Immunex and Wyeth, in accordance with Section 5.10(a)(4) below. 
  
 (2)  The
number of Bulk Drug Substance Runs currently planned by BIP, as of the Amendment No. 2 Effective Date, for the Calendar Years [*] through [*] (each, a “Transition Year,” and together, the “Transition Years”) are set
forth on Amendment No. 2 Exhibit B attached hereto and made a part hereof. The number of Bulk Drug Substance Runs set forth on Amendment No. 2 Exhibit B shall be binding on the Parties for the Calendar Year [*], subject to the other terms of
this Agreement, but shall not be binding for Calendar Years [*] and [*]. By no later than June 30 of the Calendar Years [*] and [*], BIP shall inform Immunex in writing of the actual number of Bulk Drug 
 

	*
	 
	Confidential Treatment Requested. 
 

 

 4 

 Substance Runs scheduled for the immediately following Transition Year and such written statement shall be binding on the
Parties, subject to the other terms of this Agreement. Notwithstanding anything herein to the contrary, BIP shall remain obligated to provide the Annual Minimum required under the Agreement for each Transition Year. 
  
 (3)  For Calendar Years [*] through [*] (each, a “Post-Transition Year,” and together, the
“Post-Transition Years”), BIP shall be obligated to provide the Annual Minimum of Bulk Drug Substance Runs in the [*] Biberach Facility. 
  
 (4)  BIP hereby offers Immunex and Wyeth, and Immunex and Wyeth hereby accept, [*] Bulk Drug Substance Runs, using [*], in the Original Biberach
Facility, for each Post-Transition Year. Such [*] additional Bulk Drug Substance Runs shall be considered Accepted Unused Capacity subject to Section 5.1(a)(3) of the Agreement and shall be hereinafter referred to as the “Baseline Accepted
Unused Capacity”. [*] 
  
 In addition, BIP shall offer to Immunex and Wyeth the then
available additional unused production capacity in the Original Biberach Facility beyond the Baseline Accepted Unused Capacity (the “Additional H84 Unused Capacity”) and shall make such offer in writing for each Post-Transition Year
at least [*] Calendar Years prior to the commencement of such Post-Transition Year. Any such Additional H84 Unused Capacity shall be for manufacture of the Product [*]. Upon receipt of such written notice from BIP, Immunex and Wyeth shall have a
period of [*] days in which to provide written notice to BIP that Immunex and Wyeth wish to reserve all or any portion of such Additional H84 Unused Capacity for the production of additional kg of Bulk Drug Substance and, if Immunex and Wyeth accept
any such capacity, it shall be deemed Accepted Unused Capacity subject to Section 5.1(a)(3) of the Agreement. [*] 
  
 Notwithstanding the foregoing, beginning on [*] and continuing through the end of the Supply Term, Immunex and Wyeth shall be entitled to reduce the Baseline Accepted Unused Capacity by no more than [*] per Calendar Year by providing
at least [*] prior written notice to BIP (e.g., notice by [*] for a potential reduction in the Baseline Accepted Unused Capacity effective as of [*], etc.). 
 

	*
	 
	Confidential Treatment Requested. 
 

 

 5 

  
 (5)  BIP’s obligations under Sections 5.1(a)(3)
and 24.1(d) of the Agreement shall be deemed satisfied by: (A) BIP’s offer of Bulk Drug Substance Runs during the Transition Years, as set forth in Section 5.10(a)(2) above, and (B) BIP’s offer of the Baseline Accepted Unused Capacity and
any Additional H84 Unused Capacity, as set forth in Section 5.10(a)(4) above. BIP shall have no obligation under Sections 5.1(a)(3) and 24.1(d) of the Agreement to offer Immunex and Wyeth unused production capacity in the [*] Biberach Facility.

  
 6.  Pricing of [*].    Section 5.3(c) of the Agreement shall be amended and
restated as follows: 
  
 5.3  Adjustment of Bulk Drug Substance Pricing Based on Production
Assumptions. 
  
 (c) [*] 
  
 7.  Price Adjustments Applicable to [*].    New Section 5.3(d) shall be added to the Agreement as follows: 
  

5.3  Adjustment of Bulk Drug Substance Pricing Based on Production Assumptions. 
  
 (d) [*] 
  
 8.  Extension
of Supply Term of Agreement.    Section 19.1 of the Agreement shall be amended and restated as follows: 
  
 19.1  Term; Renewal. 
  
 Unless sooner terminated pursuant to the terms of this
Agreement, the term of this Agreement shall commence upon the Effective Date and shall continue thereafter until at least [*] (the “Supply Term”). This Agreement and the Supply Term shall automatically continue from Calendar
Year-to-Calendar Year thereafter unless terminated by either Party by providing at least [*] prior written notice to the other Party, provided that neither Party may provide such notice prior to the end of the [*] Contract Year, i.e., [*]. For
purposes of this Section 19.1, Immunex and Wyeth shall be deemed the same Party. 
  
 9. [*] 
  
 10. [*] Pricing. 
 

	*
	 
	Confidential Treatment Requested. 
 

 

 6 

  
 (a)  Section 24.1(c)(3) of the Agreement shall be amended and restated
as follows: 
  
 (3)  [*] that is performed per year for Calendar Years [*], [*] and [*]
(for each of these [*] Calendar Years, the additional Bulk Drug Substance Runs made available by BIP to Immunex and Wyeth in the particular Calendar Year shall be referred to as the “Subsequent Additional Runs”), provided,
however, that the number of Bulk Drug Substance Runs that are performed in each of [*] (for the last [*] of [*]), [*], [*] and [*] that are eligible for the DM [*] pricing shall not exceed the difference between the number of actual Bulk Drug
Substance Runs that are performed between [*] to [*] and [*] Bulk Drug Substance Runs (comprised of the [*] carryover Bulk Drug Substance Runs + [*] Bulk Drug Substance Runs in [*] + [*] Bulk Drug Substance Runs in [*]), and provided further that
[*] pricing as set forth in this Section 24.1(c)(3) shall be available for no more than [*] Bulk Drug Substance Runs per Calendar Year in each of [*], [*], and [*]. 
  
 (b)  A new Section 24.1(g) shall be added to the Agreement as follows: 
  
 (g)  [*] Pricing.    In addition to the runs that are eligible for [*] pricing in each of the Calendar Years [*], [*]
and [*] as calculated under Amendment No. 1, BIP will be eligible to receive new [*] pricing, instead of [*] pricing, on certain additional Bulk Drug Substance Runs of the Product [*] in each of the years [*], [*], [*] and [*] (the
“[*]Pricing Runs”). The Bulk Drug Substance Runs that are eligible to be [*] Pricing Runs are: 
  
 (1)  any Bulk Drug Substance Runs beyond the initial [*] Bulk Drug Substance Runs in each of Calendar Years [*], [*] and [*] (i.e., those Bulk Drug Substance Runs beyond the initial [*] per Calendar Year that are not
already eligible to receive [*] pricing as calculated under Amendment No. 1) and 
  
 (2)  any Bulk Drug Substance Runs beyond the initial [*] Bulk Drug Substance Runs in Calendar Year [*]. 
  
 For purposes of calculating the [*] runs in [*] through [*] and the [*] runs in [*], Bulk Drug Substance Runs [*] shall be included; provided, however, that only Bulk Drug Substance Runs [*] are eligible to be [*] Pricing Runs that
receive the [*] 
 

	*
	 
	Confidential Treatment Requested. 
 

 

 7 

 pricing described in this paragraph. The [*] pricing for the [*] Pricing Runs shall be the then current Product Price,
plus a payment of DM [*] for each successful [*] Pricing Run of the Product [*] that results in Finished Product meeting the Specifications. Notwithstanding anything in this Agreement to the contrary, BIP shall not be entitled to receive (x) any [*]
pricing under Amendment No. 1 or any [*] pricing under this Amendment No. 2 on Bulk Drug Substance Runs [*], or (y) any [*]. 
  
 11.  Effect of Amendment No. 2 on Agreement.    Except as otherwise set forth in this Amendment No. 2, all other terms and provisions of the Agreement shall remain in full force and effect. In the
event of any conflict between the terms and conditions of the Agreement, as amended by Amendment No. 1, and the terms and conditions of this Amendment No. 2, the terms and conditions of this Amendment No. 2 shall control. 
  
 12.  Counterparts.    This Amendment No. 2 may be executed in counterparts, each of which shall be
deemed an original and all of which shall constitute together one and the same instrument. 
  
 [This space is intentionally
left blank.] 
  
 

	*
	 
	Confidential Treatment Requested. 
 

 

 8 

  
 IN WITNESS WHEREOF, the Parties have, by their duly authorized persons, executed
this Amendment No. 2 as of the Amendment No. 2 Effective Date. 
  
 
	 IMMUNEX CORPORATION
 	 	  	 	 WYETH
 
	 
	 By:
 	 	 /S/    PEGGY V. PHILLIPS
 	 	  	 	 By:
 	 	 /S/    JEFFREY S. SHERMAN
 
	 
	 Name:
 	 	 Peggy V. Phillips
 
	 	  	 	 Name:
 	 	 Jeffrey S. Sherman
 

	 
	 Title:
 	 	 Executive Vice President Chief Operating Officer
 
	 	  	 	 Title:
 	 	 Vice President & Associate General Counsel
 

	 
	 Date:
 	 	 June 3, 2002
 
	 	  	 	 Date:
 	 	 June 5, 2002
 

 
  
 
	 
	 BOEHRINGER INGELHEIM PHARMA KG
 	 	  	 	  
	 
	 PPA
 	 	  	 	 PPA
 
	 
	 By:
 	 	 /S/    ROLF WERNER  
 
	 	  	 	 By:
 	 	 /S/    WOLFRAM CARIUS        
 

	 
	 Name:
 	 	 Rolf Werner
 
	 	  	 	 Name:
 	 	 Wolfram Carius
 

	 
	 Title:
 	 	 Head CD Biopharma
 
	 	  	 	 Title:
 	 	 Head Biopharmaceuticals
 

	 
	 Date:
 	 	 June 18, 2002
 
	 	  	 	 Date:
 	 	 June 18, 2002
 

 
  
 Appendices: 
  
 
	 Amendment No. 2
 Exhibit A:
 	  	 [*]
 (former Appendix LOI—1)
 
	 Amendment No. 2
 Exhibit B:
 	  	 Implementation [*] in [*] Plant (former Appendix LOI—2.2)
 
	 Amendment No. 2
 Exhibit C:
 	  	 Master Plan [*] BackUp (former Appendix LOI—5.2)
 
	 Amendment No. 2
 Exhibit D:
 	  	 Implementation [*] into [*] Plant (former Appendix LOI—2.1) (attached for reference)
 

 
 

	*
	 
	Confidential Treatment Requested. 
 

 

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}]]